Drug profile · INN
cidofovir
VISTIDE
cidofovir (VISTIDE) is a human herpesvirus 1 dna polymerase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — cidofovir
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 10
- Data quality
- 0.84
Quick answer
cidofovir (VISTIDE) is a human herpesvirus 1 dna polymerase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Human herpesvirus 1 DNA polymerase inhibitor
Primary target: DNA polymerase catalytic subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is cidofovir?
cidofovir (VISTIDE) is a human herpesvirus 1 dna polymerase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for cidofovir?
VISTIDE is a marketed brand name for cidofovir. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cidofovir?
cidofovir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.